David S. Bredt, M.D., Ph.D.

Global Head Neuroscience Discovery Site Head, La Jolla Janssen Pharmaceutical Companies of Johnson & Johnson

David Bredt currently heads Janssen’s Neuroscience Discovery and Biomarker groups and is the site head for Janssen’s R&D facility in La Jolla. Before joining Janssen, David led Neuroscience Research and Early Development at Eli Lilly and Company delivering three-to-four clinical candidates a year.

Prior to working in industry, David was Professor of Physiology at the University of California, San Francisco. His research on nitric oxide, glutamate receptor signaling, and synaptic plasticity has yielded more than 200 papers, which have been cited more than 70,000 times in the scientific literature. He has served on the Neuroscience Forum, Institute of Medicine for National Academy of Sciences and the Advisory Panel for the National Institute of Neurological Disorders and Stroke.

David has won numerous research awards, including ones from the American College of Neuropsychopharmacology, the American Society of Pharmaceuticals and Experimental Therapeutics, the Arnold and Mabel Beckman Foundation, the EJLB Neuroscience Foundation, the McKnight Foundation and the Klingenstein Foundation. He also has received the Charles E. Culpeper Foundation Award, the Searle Scholars Award and the Alfred P. Sloan Award. In 2016, he received an honorary doctorate from the Western University of Health Sciences.

David graduated summa cum laude in Chemistry at Princeton University and received his medical degree and a doctorate at Johns Hopkins University.